AstraZeneca plc Given Sell Rating at Societe Generale (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating restated by research analysts at Societe Generale in a report released on Wednesday. They currently have a GBX 3,700 ($62.07) price target on the stock. Societe Generale’s price objective points to a potential downside of 9.72% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Monday. They now have a GBX 4,500 ($75.49) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “underweight” rating on shares of AstraZeneca plc in a research note on Friday, August 8th. They now have a GBX 3,700 ($62.07) price target on the stock. Finally, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca plc in a research note on Monday, August 4th. They now have a GBX 3,721.79 ($62.44) price target on the stock. Six analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of GBX 4,055.48 ($68.03).
Shares of AstraZeneca plc (LON:AZN) opened at 4102.50 on Wednesday. AstraZeneca plc has a 52-week low of GBX 3086.50 and a 52-week high of GBX 5750.00. The stock has a 50-day moving average of GBX 4342.41 and a 200-day moving average of GBX 4193.81. The company’s market cap is £51.815 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.